

Kenneth R Carson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1183433/publications.pdf>

Version: 2024-02-01

36
papers

2,254
citations

471509

17
h-index

454955

30
g-index

37
all docs

37
docs citations

37
times ranked

3256
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	1.4	829
2	Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Lancet Oncology</i> , The, 2009, 10, 816-824.	10.7	433
3	Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. <i>Cancer</i> , 2014, 120, 2464-2471.	4.1	113
4	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2019, 94, 1176-1184.	4.1	112
5	The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. <i>Cancer</i> , 2019, 125, 1507-1517.	4.1	106
6	Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3217-3222.	1.6	78
7	Statins Are Associated With Reduced Mortality in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4008-4014.	1.6	76
8	Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. <i>Thrombosis Research</i> , 2015, 135, 616-620.	1.7	75
9	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. <i>British Journal of Haematology</i> , 2016, 172, 535-544.	2.5	71
10	Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw264.	6.3	61
11	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2015, 6, 211-218.	1.0	47
12	Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: Diagnostic implications. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 159-167.	1.2	39
13	Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma. <i>Oncologist</i> , 2013, 18, 1074-1079.	3.7	36
14	Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. <i>EBioMedicine</i> , 2019, 46, 170-183.	6.1	26
15	Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating. <i>Leukemia and Lymphoma</i> , 2009, 50, 323-324.	1.3	20
16	Venous thromboembolism in multiple myeloma is associated with increased mortality. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1203-1210.	2.3	19
17	Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. <i>Leukemia and Lymphoma</i> , 2016, 57, 1191-1193.	1.3	18
18	Progressive multifocal leukoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 301-304.	2.5	16

#	ARTICLE	IF	CITATIONS
19	Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 69-74.	1.0	14
20	Surveillance Imaging for Lymphoma: Pros and Cons. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e388-e395.	3.8	11
21	Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium. <i>Blood</i> , 2013, 122, 3032-3032.	1.4	11
22	Variability in the Practice of Fertility Preservation for Patients with Cancer. <i>PLoS ONE</i> , 2015, 10, e0127335.	2.5	10
23	Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data. <i>Journal of Medical Economics</i> , 2016, 19, 965-972.	2.1	8
24	Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 744-748.	0.4	8
25	Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL). <i>Blood</i> , 2014, 124, 4434-4434.	1.4	6
26	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. <i>Blood</i> , 2015, 126, 574-574.	1.4	2
27	Psoas Cross-Sectional Area As Radiographic Measure Of Sarcopenia Does Not Predict Overall Survival In Multiple Myeloma. <i>Blood</i> , 2013, 122, 5326-5326.	1.4	2
28	Rituximab-Associated Progressive Multifocal Leukoencephalopathy (PML) in HIV-Negative Patients: An Updated Report of 231 Confirmed Cases from the Southern Network on Adverse Reactions (SONAR)/Washington University Collaboration (2000-2012). <i>Blood</i> , 2014, 124, 4456-4456.	1.4	2
29	Outcomes of Chemotherapy Treatment in Elderly Patients with Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 3545-3545.	1.4	2
30	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
31	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
32	Reply to S. Suissa et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1378-1379.	1.6	0
33	Zoledronic Acid Improves Overall Survival Compared To Pamidronate In Multiple Myeloma. <i>Blood</i> , 2013, 122, 3182-3182.	1.4	0
34	Clinical and Economic Burden Of Peripheral T-Cell Lymphoma In The United States. <i>Blood</i> , 2013, 122, 2963-2963.	1.4	0
35	Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients. <i>Blood</i> , 2013, 122, 1785-1785.	1.4	0
36	Statin Therapy Improves Multiple Myeloma (MM) Specific Survival. <i>Blood</i> , 2015, 126, 879-879.	1.4	0